The National Cancer Institute has an upcoming phase I trial assessing the safety and feasibility of an anti-CD30 CAR-T cell treatment in advanced CD30-expressing lymphomas, including ALCL and PTCL-NOS. The gene discussed is TNFRSF8; the disease is anaplastic large cell lymphoma.